Singapore-based healthcare-dedicated asset management company CBC Group (CBC) announced on Friday that it has completed the acquisition of Belgium-based UCB's mature neurology and allergy business in China for USD680m, in partnership with Mubadala Investment Company.

This transaction includes leading brands such as Keppra, Vimpat, Neupro, Zyrtec, Xyzal and the Zhuhai manufacturing facility. It aligns with CBC's buyout strategy, strengthening its presence in China's USD33bn CNS biopharma market. The acquisition aims to establish NeuroGen Pharma, a new company focused on neurology innovation, supported by an experienced management team.

NeuroGen Pharma plans to enhance patient outcomes through cutting-edge research and therapies, addressing China's evolving neurology needs. CBC's proprietary investor-operator model will drive operational efficiencies and innovation, leveraging synergies with Mubadala. Combined portfolio sales reached EUR131m in 2023, reflecting the assets' strong market potential. This marks a continued collaboration between CBC and Mubadala, building on investments like the CBC Healthcare Infrastructure Platform and Hasten's USD315 million fundraising.